1. Home
  2. FGII vs AGEN Comparison

FGII vs AGEN Comparison

Compare FGII & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FGII

FG Imperii Acquisition Corp. Class A Ordinary Shares

SELL

Current Price

$10.03

Market Cap

288.0M

Sector

Finance

ML Signal

SELL

Logo Agenus Inc.

AGEN

Agenus Inc.

BUY

Current Price

$6.12

Market Cap

335.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FGII
AGEN
Founded
2025
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.0M
335.6M
IPO Year
2025
1999

Fundamental Metrics

Financial Performance
Metric
FGII
AGEN
Price
$10.03
$6.12
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $26.33
AVG Volume (30 Days)
93.1K
★ 1.0M
Earning Date
N/A
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.96
Revenue
N/A
★ $42,877,086.00
Revenue This Year
N/A
$9.64
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$6.29
Revenue Growth
N/A
★ 89.95
52 Week Low
$9.86
$2.71
52 Week High
$10.04
$10.19

Technical Indicators

Market Signals
Indicator
FGII
AGEN
Relative Strength Index (RSI) 61.26 35.61
Support Level $10.01 $2.96
Resistance Level $10.04 $8.64
Average True Range (ATR) 0.01 0.59
MACD -0.00 -0.28
Stochastic Oscillator 83.33 3.82

Price Performance

Historical Comparison
FGII
AGEN

About FGII FG Imperii Acquisition Corp. Class A Ordinary Shares

FG Imperii Acquisition Corp is a blank check company incorporated in the Cayman Islands. The company was formed for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: